Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CMVLF)
OTHER OTC:CMVLF
Holding CMVLF?
Track your performance easily
CMVLF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.49 - $3.50
Previous Close$1.99
Volume8.00
Average Volume (3M)N/A
Market Cap
$112.64M
Enterprise Value$27.38M
Total Cash (Recent Filing)$136.71M
Total Debt (Recent Filing)$51.45M
Price to Earnings (P/E)―
Beta5.41
Next Earnings
May 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.03
Shares Outstanding45,565,810
10 Day Avg. Volume0
30 Day Avg. VolumeN/A
Standard Deviation0.34
R-Squared0.06
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.20
Price to Sales (P/S)16.94
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue17.50
Enterprise Value/Gross Profit1.52K
Enterprise Value/Ebitda-0.44
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Cellectis SA News
PremiumCompany Announcements
Cellectis SA: Financial Growth Amidst Strategic Partnerships
Ownership Overview
―
Insiders
1.14% Mutual Funds
0.02% Other Institutional Investors
98.84% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CMVLF FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $1.49 and its highest was $3.50 in the past 12 months.
What is Cellectis SA’s market cap?
Currently, no data Available
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is May 07, 2025 which is in 137 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on Nov 04, 2024. The company reported -$0.222 earnings per share for the quarter, beating the consensus estimate of -$0.229 by $0.007.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Overvalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,093,636 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -$0.222 in its last earnings report, beating expectations of -$0.229. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Cellectis SA?
Currently, no hedge funds are holding shares in CMVLF
---
Cellectis SA Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-44.41%
12-Months-Change
Fundamentals
Return on Equity
-101.50%
Trailing 12-Months
Asset Growth
88.78%
Trailing 12-Months
Company Description
Cellectis SA
Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following business segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.
---
CMVLF Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for Cellectis, driven by strategic partnerships, financial strength, and progress in clinical trials. However, challenges include the de-prioritization of certain assets and delays in data release.Read More>---
Technical Analysis
Adaptimmune Therapeutics
―
Crispr Therapeutics AG
―
Intellia Therapeutics
―
Editas Medicine
―
---